However, despite multiple benefits and advantages they offer, their implementation at the industrial level in the pharmaceutical industry is not straightforward and remains limited 6 , due to several challenges. These are generally related to the fact that enzymes are often used in their "free" form, functioning as soluble homogeneous biocatalysts that are difficult to reuse, restricted to batch reactors, and which typically exhibit limited stability 7 . Additionally, enzymes tend to suffer from substrate and/or product inhibition, and -in some cases -unfavorable thermodynamic equilibria for the targeted reactions. The quality of the final product can also be compromised by free enzyme deactivation, resulting in complex purification processes 8 . Some of these challenges can be mitigated by immobilizing enzymes on solid supports , which allows for their recovery and reuse, and facilitates their implementation in continuous flow processes . Moreover, immobilization often results in enhancing the enzyme stability and tolerance to organic solvents . The transfer from batch to continuous-flow processing is of major industrial interest as it increases the productivity of (bio)catalytic transformations and the efficiency of subsequent/coupled unit operations (e.g. crystallization), thus improving the overall process's economic viability . Enzymatic processes arguably pave the way for the development of intensified industrially relevant organic synthesis . Enzyme immobilization can be performed in various ways, and on a wide range of functional materials such as polymeric resins, inorganic powders, biopolymers, or membranes . Ready-to-use synthetic resins are the traditional ubiquitous carrier, allowing to run biocatalytic reactions in heterogeneous catalysis mode, and to easily recover and reuse the biocatalysts.